CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new therapeutic strategies for pancreatic ductal adenocarcinoma by targeting the tumor microenvironment and its resident cells. It focuses on modulating specific cellular pathways to inhibit fibrosis and improve drug delivery using innovative compounds and hydrogels.
Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is the fourth-leading cause of cancer related mortality and is predicted to be the second leading cause of cancer death by 2030.
Widely regarded as a death sentence, the 5-year survival rate is less than 5% and this figure has not changed over the past four decades due to lack of effective therapies. PDAC develops in a fibrotic setting that hampers drug delivery and modulates immune response & tumour growth/disse…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
